Melanoma Clinical Trial
— SCSESOfficial title:
Skin Cancer Screening Education Study
Verified date | May 2019 |
Source | Association of Dermatological Prevention, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall aim of this population-based screening study is to assess whether the skin cancer
screening training of family physicians and dermatologists leads to improved screening
outcomes. The training course aims to increase the accuracy of detecting early stages of skin
cancer. Screening outcomes of an intervention region (Calgary, Canada) in which physicians
receive training will be compared with screening outcomes of a control region (Edmonton,
Canada) where no physician training is administered.
The investigators will determine whether:
- clinical screening outcomes are more favorable in the group of trained physicians
compared to non trained physicians
- there is an increase of knowledge about skin cancer screening among trained physicians,
compared to non trained physicians
- skin cancer screenings are associated with psycho-social harms
- population-based screening has an effect on the overall incidence and
stage-specific-incidence of skin cancer in Alberta
The investigators are aiming to recruit 100 physicians per region (total of 200 physicians)
who will screen 40,000 to 80,000 individuals over a period of 20 months.
Status | Active, not recruiting |
Enrollment | 113 |
Est. completion date | September 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. Screenees - Male and female residents of Alberta mainly living and receiving care in Edmonton or in Calgary - Age 20+ - English-speaking - Individuals who consent to participate 2. Physicians - Registered dermatologists and family physicians administering care either in Edmonton or in Calgary - English-speaking - Physicians who consent to participate Exclusion Criteria: Physicians who have undergone special training in skin cancer screening within the last 2 years |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary, University of Alberta | Calgary, Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
Association of Dermatological Prevention, Germany | University of Alberta, University of Calgary |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the diagnostic accuracy including knowledge on skin cancer screening | Educational outcomes of physicians will be measured pre- and post-training using knowledge tests in the intervention and control region | month 1 pre-training (intervention and control region), month 1 post-training (intervention region only), and month 12 (both regions) | |
Primary | Number needed to screen (NNS) to identify 1 skin tumor and number needed to excise (NNE) to identify 1 skin tumor | Case report forms will be analyzed to determine clinical screening outcomes such as the NNS, NNE and tumor thickness. | 20 months | |
Primary | Patient-rated well-being | A patient questionnaire will be used to assess psycho-social harms of skin cancer screenings. | 20 months | |
Primary | Trends of overall skin cancer incidence and stage-specific-incidence | Up to 6 years (2012-2018) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|